News and features

Removing a single protein from cells that surround tumours can improve the sensitivity of certain cancers to immunotherapy, researchers have found.

The first UK trial to test the benefits of proton beam therapy for certain patients with breast cancer has launched in the UK. The trial will compare proton beam therapy – which can target radiotherapy beams more precisely – with standard radiotherapy for patients who are at greater risk of long-term heart problems after radiotherapy treatment.

A new type of treatment strategy targeting a protein found on the surface of the most lethal prostate cancers could hold promise against the disease.

By studying rare cases of identical twins with leukaemia, scientists have shed new light on the origins of the most common type of childhood cancer – confirming it originates in the womb but that events after birth determine whether or not clinical leukaemia develops.

The Wren Chapel at the Royal Hospital Chelsea was full of guests and famous faces on 6 December, celebrating the 20th Carols from Chelsea service in support of The Institute of Cancer Research, London.

We have picked 10 exciting scientific discoveries from the past academic year that brilliantly showcase the quality, breadth and strategic impact of our research.

Scientists have created a comprehensive tool for predicting an individual’s risk of developing prostate cancer, which they say will help ensure that those men at greatest risk will receive the appropriate testing while reducing unnecessary – and potentially invasive – testing for those at very low risk.

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial.

The latest major breakthrough in cancer is a drug called capivasertib, which has shown ‘remarkable’ results against advanced breast cancer in its first phase III trial. Henry French gives an update

Scientists and clinicians at The Institute of Cancer Research, London, and from around the world, have shared their condolences and celebrated the many achievements of Professor Daniel Catovsky, who died last week.

The Institute of Cancer Research, London, and biopharmaceutical company Apollo Therapeutics have announced a new collaboration that will advance the development of new cancer drugs, combining the strengths and expertise of both organisations.

Scientists have revealed the inner workings of a key protein involved in a wide range of cellular processes – potentially paving the way for better and less toxic cancer drugs.